ASLAN Partners Hope Foundation To Develop Cancer Care Mobile Application

Taipei, Taiwan, 25 July 2017 – ASLAN Pharmaceuticals (ASLAN, 6497.TT), a biotech company focused on the development of immunotherapies and targeted agents for Asia prevalent tumour types, today announced that it will be partnering Taiwan’s HOPE FOUNDATION for CANCER CARE (HOPE) to develop a new digital application to assist cancer patients in managing their care. Funded by a grant from ASLAN, the new mobile application will help patients track their medical appointments, follow-up treatments and medications via their mobile phones. Personal patient information and treatment records will be digitally recorded and stored, which patients can access easily and share with their doctors and their family members. The app will be made available for free to all cancer patients in Taiwan. According to the National Health Administration’s latest Cancer Registry Annual Report, Taiwan saw 103,147 new cases of cancer in 2014[1].

Commenting on the partnership, Dr Hsieh Chih-Yi, General Manager of ASLAN Pharmaceuticals, Taiwan, said:

“ASLAN is delighted to work with the HOPE Foundation, and to contribute to the development of this new application. The mobile based nature of the app will provide greater convenience and help with patient tracking, making life easier for Taiwanese patients, their doctors, and their caregivers.”

Dr Wang Cheng-hsu, Chairman of HOPE, said: “People still have an evasive attitude when faced with cancer and avoid reaching out for help due to irrational fears towards treatment. Patients and their caregivers need to have a better understanding of cancer and how proper patient care can help them survive the disease. We are very pleased therefore to work with ASLAN to develop the ‘HOPE Passport App’, which, through digital technology, go a long way in helping cancer patients in Taiwan.”

The mobile application is expected to launch in second half of 2018.

Back to news